A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer

Harold J. Burstein, Anna Maria Storniolo, Sandra Franco, +5

Annals of Oncology

Metastatic Breast CancerBreast OncologyMedicineLapatinib MonotherapyPathology +5

Pelvic examination, tumor marker level, and gray-scale and doppler sonography in the prediction of pelvic cancer

Lynda D. Roman, Laila Muderspach, S. Stein, +3

Obstetrics and Gynecology

Updated Survival Analysis of a Randomized Study of Lapatinib Alone or in Combination with Trastuzumab in Women with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab Therapy.

Kimberly Blackwell, Harold J. Burstein, George W. Sledge, +5

Cancer Research

Lapatinib AloneLapatinib 1500Breast OncologyOncologyRandomized Study +10

Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer

Beth Sherrill, Mayur M. Amonkar, S. Stein, +3

British Journal of Cancer

Metastatic Breast CancerBreast OncologyMedicinePharmacologyPathology +5

Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): Genomic and updated efficacy data

Charles E. Geyer, Anne Marie Martin, B. Newstat, +6

Journal of Clinical Oncology

Breast OncologyL+cvs CHer2 Mrna LevelsPathologyCancer Biology +17

The Signature Program: Bringing the Protocol to the Patient

BP Kang, Eric D. Slosberg, Susan Snodgrass, +5

Clinical Pharmacology & Therapeutics

PathologyProtocol ComplianceEarly-phase Clinical DevelopmentHealth LawTumor Biology +19

COMBO-FISH for focussed fluorescence labelling of gene domains: 3D-analysis of the genome architecture of abl and bcr in human blood cells

Jutta Schwarz‐Finsterle, S. Stein, Carla Grosmann, +7

Cell Biology International

Gene DomainsGeneticsDna AnalysisBlood CellMolecular Biology +14

Blood loss in major lipoplasty procedures with the tumescent technique*

Firas R. Karmo, Michael F. Milan, S. Stein, +1

Aesthetic Surgery Journal

Investigation of tumor biomarkers as response predictors in a monotherapy study with lapatinib (L) as a first line treatment in ErbB2 amplified women with breast cancer

Henry Gómez, Miguel A. Chavez, Dinesh Chandra Doval, +7

Journal of Clinical Oncology

Tumor BiologyResponse PredictorsMetastatic Breast CancerBreast OncologyMedicine +12